Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Canagliflozin→

Canagliflozin PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
842133-18-0
Molecular formula
C24H25FO5S
Molecular weight
444.52 g/mol
Drug class
Selective sodium-glucose cotransporter 2 (SGLT2) inhibitororal antihyperglycaemic
Mechanism of action
Inhibits SGLT2 in the proximal renal tubule, reducing reabsorption of filtered glucose and increasing urinary glucose excretion. This lowers blood glucose and also affects intraglomerular haemodynamics and renal/cardiovascular risk pathways.
Indications / reported uses
  • Glycaemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise
  • Reduction of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease
  • Reduction of risk of end-stage kidney disease, doubling of serum creatinine, cardiovascular death and hospitalisation for heart failure in adults with type 2 diabetes and diabetic nephropathy with albuminuria, under the applicable US label

Sources: US DailyMed — INVOKANA (canagliflozin) · FDA prescribing information · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Selective sodium-glucose cotransporter 2 (SGLT2) inhibitor; oral antihyperglycaemic

Mechanism of action

Inhibits SGLT2 in the proximal renal tubule, reducing reabsorption of filtered glucose and increasing urinary glucose excretion. This lowers blood glucose and also affects intraglomerular haemodynamics and renal/cardiovascular risk pathways.

General use cases

  • Glycaemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise
  • Reduction of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease
  • Reduction of risk of end-stage kidney disease, doubling of serum creatinine, cardiovascular death and hospitalisation for heart failure in adults with type 2 diabetes and diabetic nephropathy with albuminuria, under the applicable US label

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Canagliflozin PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Canagliflozin Permitted Daily Exposure (PDE) report (the Canagliflozin PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Canagliflozin Occupational Exposure Limit (OEL) report (the Canagliflozin OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.